![Kreske Nickelsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kreske Nickelsen
Algemeen Directeur bij Joint Polish Investment Fund Management BV
Actieve functies van Kreske Nickelsen
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Joint Polish Investment Fund Management BV
![]() Joint Polish Investment Fund Management BV Investment ManagersFinance Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands. | Algemeen Directeur | 01-01-2015 | - |
Private Equity Investor | 01-01-2015 | - | |
Phase2 Microtechnologies, Inc.
![]() Phase2 Microtechnologies, Inc. Electronic ComponentsElectronic Technology Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA. | Directeur/Bestuurslid | - | - |
Loopbaan van Kreske Nickelsen
Eerdere bekende functies van Kreske Nickelsen
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Voorzitter | - | 17-02-2014 |
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Private Equity Investor | 01-05-2006 | 01-11-2011 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Directeur/Bestuurslid | 12-01-2010 | - |
Opleiding van Kreske Nickelsen
INSEAD | Masters Business Admin |
Statistieken
Internationaal
Oostenrijk | 3 |
Nederland | 3 |
Frankrijk | 2 |
Operationeel
Private Equity Investor | 2 |
Director/Board Member | 2 |
Chairman | 1 |
Sectoraal
Health Technology | 3 |
Finance | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
Joint Polish Investment Fund Management BV
![]() Joint Polish Investment Fund Management BV Investment ManagersFinance Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands. | Finance |
Phase2 Microtechnologies, Inc.
![]() Phase2 Microtechnologies, Inc. Electronic ComponentsElectronic Technology Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA. | Electronic Technology |
- Beurs
- Insiders
- Kreske Nickelsen
- Ervaring